Empowered Patient Podcast

Joe Todisco, CEO of CorMedix, is developing a product that has broad spectrum activity against bacteria and fungus to impact the safety of receiving hemodialysis through a central venous catheter. With the recent acceptance by the FDA of the submission for DefenCath, CorMedix is hopeful of obtaining FDA approval for this therapeutic to prevent bloodstream infections. Since the active ingredient is not an antibiotic, the drug does not further the problem of antibiotic resistance. Joe explains, "The lead indication for the product is for the reduction in risk associated with catheter-related bloodstream infections in hemodialysis patients undergoing hemodialysis with a central venous catheter, CVC. Catheter-related bloodstream infections, or CRBSIs, are one of the most severe adverse consequences associated with getting hemodialysis through a CVC. The incidence rate in the general population is about 25% to 33%, and they can be fatal up to 25% of the time. So it's a critical unmet medical need. There is no cur